Q-omics provides the consensus-scored CAPNS2 profile across patient tissues and cancer cell-line models. CAPNS2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CAPNS2 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, CAPNS2 RNA expression shows 14,060 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, LUSC, and GBM as cancer lineages where CAPNS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAPNS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAPNS2 survival associations across molecular data types. CAPNS2 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAPNS2 RNA expression–survival associations across cancer types. High CAPNS2 expression shows unfavorable associations in BRCA, LGG and LIHC, but favorable associations in UCEC, ACC and LAML. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for CAPNS2 RNA expression.
This table summarizes CAPNS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CAPNS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAPNS2 shows lower tumor expression in THCA, PRAD, HNSC and BRCA and higher tumor expression in LUSC and COAD. The LUSC box plot shows higher CAPNS2 RNA expression in tumor versus normal tissue (log2 FC = +3.777, t-test p < 0.001).
This table shows molecular features associated with CAPNS2 in patient tissues and cancer cell lines. In patient samples, CAPNS2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CAPNS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
